AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy
Withdrawn
- Conditions
- PregnancyPregnant WomenPregnancy Outcome
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05847140
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Active, not recruiting
- Conditions
- Biliary Tract Cancer
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 235
- Registration Number
- NCT05835778
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Phase 3
Active, not recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05835310
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
Phase 2
Withdrawn
- Conditions
- Neurofibromatosis Type 1Post-operativePlexiform Neurofibromas
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05825365
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 296
- Registration Number
- NCT05826366
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT05818514
- Locations
- 🇸🇪
Research Site, Solna, Sweden
An ADME Study of [14C]AZD0780 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: AZD0780 tabletDrug: [14C]AZD0780 Solution for InfusionDrug: [14C]AZD0780 Oral Solution
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT05817461
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
Active, not recruiting
- Conditions
- Lung Malignancy
- Interventions
- Other: Participant Cohort
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT05817110
- Locations
- 🇹🇷
Research Site, Mersin, Turkey
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Active, not recruiting
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT05809934
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT05801029
- Locations
- 🇹🇭
Research Site, Songkhla, Thailand
© Copyright 2025. All Rights Reserved by MedPath